5 results about "Sodium Chloride Injection" patented technology

The application belongs to the technical field of medicine, and relates to a compound composition, a preparation method and application, in particular to a compound sodium salicylate composition for treating acute pancreatitis and a preparation method. The compound sodium salicylate composition comprises quercetin, diammonium glycyrrhizinate and sodium salicylate, wherein the mass ratio of quercetin, diammonium glycyrrhizinate and sodium salicylate is 1-5:5-20:50-200. When the compound sodium salicylate composition is an injection, it comprises quercetin, diammonium glycyrrhizinate, sodium salicylate, 1,2-propanediol, sodium bisulfite, dimethyl sulfoxide and 0.9% sodium chloride injection. The volume ratio of 1,2-propanediol and dimethyl sulfoxide in the injection is 14-20% and 0.25-1% respectively; and the mass / volume ratio of sodium bisulfite in the injection is 0.1-0.3%. The compound sodium salicylate composition can significantly reduce amylase, lipase, IL-6 and IL-1beta, and can be used for preparing a medicine for treating pancreatitis.

The present disclosure relates to the field of biomedicine, and discloses a nutritional composition for intervention or treatment of autism and a preparation method thereof, aiming to solve the problems of safety, compliance and insufficient targeting mechanism of existing intervention programs for social impairment of autism. The composition comprises leucine, isoleucine and valine in a molar ratio of 1:1:1, with a total concentration of 0.753 mg / kg of body weight, in the form of oral liquid, and a pH of 6.87.4. The preparation method comprises weighing the amino acids according to the molar ratio, dissolving them in 0.9% sodium chloride injection, filtering, dispensing and sealing. The present application can safely and effectively improve the social impairment of autism patients and plays a role by up-regulating the expression of MyT1L in the hippocampus.

This invention relates to the field of pharmaceutical analysis technology, and provides a method for detecting enantiomers in peramivir sodium chloride injection. The method employs high-performance liquid chromatography (HPLC), with the following chromatographic conditions: a column packed with α1-acidic glycoprotein-bonded silica gel; a mobile phase consisting of a mixture of 0.02 mol / L ammonium dihydrogen phosphate solution and 0.02 mol / L diammonium hydrogen phosphate solution at a volume ratio of 45:55 to 55:45; a detection wavelength of 205 nm; a flow rate of 0.25 to 0.35 mL / min; and a column temperature of 18 to 22 °C. Before detection, a test solution, a reference solution, and a system suitability solution are prepared, and each solution is accurately injected into the HPLC system. The chromatograms are recorded, and the enantiomer content is calculated. The advantages of this invention are: simple operation, no sodium chloride interference, and accurate quantitative detection of enantiomers in peramivir sodium chloride injection.

This invention discloses a water softening system, relating to the technical field of water softening systems. It includes a bottom support assembly, with a water softening component mounted on top. The top of the water softening component is connected to an evaporator via a pipe. The system, in conjunction with the water softening component, filter screen, and salt filter, performs preliminary filtration of the incoming raw water. Then, sodium chloride is injected into the catalyst injection chamber through the sodium chloride injection end. The presence of two convection devices at an angle increases the dissolved oxygen required during the delivery of the sodium chloride aqueous solution. Calcium ions are then adsorbed through a calcium ion adsorption alumina membrane. A resistor, connected to a controller and an internal power supply, electrically connects the system, causing an induction coil to rotate under the influence of a drive motor. This generates a magnetic field at the bottom of the water softening chamber, adsorbing calcium, sodium, and magnesium ions in the raw water, effectively improving the water softening efficiency.

This invention relates to an injectable paclitaxel formulation designed to enhance solubility and stability. The formulation comprises paclitaxel at a concentration of 6 to 12 mg / mL, with Vitamin E Polyethylene Glycol Succinate (TPGS) serving as a surfactant and solubilizer in concentrations ranging from 300 mg / mL to 600 mg / mL. Polyethylene glycol 300 (PEG 300) acts as a stabilizer, and citric acid is included as a buffering agent, along with water for injection. The formulation is stable at room temperature for about 27 hours after dilution in infusion liquids such as 5% dextrose injection USP, 0.9% sodium chloride injection USP, 5% dextrose and 0.9% sodium chloride injection USP and 5% dextrose in Ringer's Injection solutions. The diluted formulation forms a nano micellar solution with micelles ranging from 10 to 100 nm in size, ensuring a stable and clear solution for intravenous administration of paclitaxel, thus improving safety and efficacy.